Sentences with phrase «conditioning program in the country»

We had the best strength and conditioning program in the country.

Not exact matches

Based in Carlsbad, California, Jazzercise's instructors teach its total - body conditioning program to almost half a million participants each year in the United States and more than 30 other countries.

Airports across the country are seeing lines balloon in size, thanks to a «perfect storm» of conditions — the number of airline passengers has increased to 700 million; there's massive attrition of TSA security screeners each week; TSA has cut staff by 10 percent over the last three years; and not enough passengers have enrolled in TSA's PreCheck program, the Associated Press reports.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

One official, who spoke on the condition of anonymity to discuss internal deliberations, said that Mr. Trump was sympathetic to the plight of the young immigrants, known as Dreamers — many have known life only in the United States and have few connections to the countries of their birth — but had been told by Justice Department lawyers that his predecessor's program would not survive a court challenge.

In accordance with our policies, regulations and conditions, citizens of these countries can not take part in the crowdfunding prograIn accordance with our policies, regulations and conditions, citizens of these countries can not take part in the crowdfunding prograin the crowdfunding program.

If you are involved in a private youth sports program which plays on publicly - owned fields, diamonds, rinks, or courts, or are in local government, you have probably been hearing a lot lately about what is being dubbed the «power of the permit»: the authority municipalities and towns around the country are using to condition use of their athletic facilities by private programs on compliance with state concussion safety laws from which they would otherwise be exempt, or, in an increasing number of instances, to fill gaps in their state's law.

This story is the first in a series that will examine top - performing preschool programs in the U.S., Head Start, preschool solutions found in other countries, the condition of preschool teachers and the political future of preschool.

Strengthen their commitment to the free and unrestricted exchange of meteorological and related data and products; Increase the volume of data and products exchanged to meet the needs of WMO Programs; Assist other Members, to the extent possible, and as agreed, by providing additional data and products in support of time - sensitive operations regarding severe weather warnings; Strengthen their commitments to the WMO and ICSU WDCs in their collection and supply of meteorological and related data and products on a free and unrestricted basis; Implement the practice on the international exchange of meteorological and related data and products, as described in Adopts (1) to (3) above; Make known to all Members, through the WMO Secretariat, those meteorological and related data and products which have conditions related to their re-export for commercial purposes outside of the receiving country or group of countries forming a single economic group; Make their best efforts to ensure that the conditions which have been applied by the originator of additional data and products are made known to initial and subsequent recipients; *» Free and unrestricted» means non-discriminatory and without charge.

Germany's surprising performance was driven by excellent investment conditions and demand pull - forward prior to a cut of the country's Feed - in - Tariff (FIT) incentive program in July.»

In accordance with our policies, regulations and conditions, citizens of these countries can not take part in the crowdfunding prograIn accordance with our policies, regulations and conditions, citizens of these countries can not take part in the crowdfunding prograin the crowdfunding program.

The U.S. International CK Caribbean CK CK NewsWe believe career guidance programs can help improve economic conditions for people in other countries.

Build On - 2011 - 2014 A volunteer organization allowing students to participate in weekly community service, and help end poverty and illiteracy in third world countries * Habitat for Humanity - 2013 - 2015 A volunteer program focused on improving living conditions by building and renovating more affordable homes for low income families.

Community Involvement * Build On - 2011 - 2014 A volunteer organization allowing students to participate in weekly community service, and help end poverty and illiteracy in third world countries * Habitat for Humanity - 2013 - 2015 A volunteer program focused on improving living conditions by building and renovating more affordable homes for low income families.

She highlighted the work of justice reinvestment programs such as «Clean Slate Without Prejudice» in Redfern and urged the government to review such successful initiatives for replication «while adapting these community led initiatives to local conditions, in targeted areas throughout the country».

Since the early 2000s, the Russian government has worked to solve the problem of the country's decaying housing stock, through the implementation of a number of federal programs aimed at improving the living conditions of citizens and stimulating growth in demand for real estate — and at the same time, for the services of real estate brokers.